NAV
17.47(0.22%)Fund Size (CR)
₹1,936.05Expense Ratio
2.07Scheme Type
Active FundValue Research
Min. investment
₹100Minimum Additional Investment
₹100Minimum SIP Investment
₹100Minimum Withdrawal
₹100Exit Load
1%Return Since Launch
34.28%
- 3M
- 6M
- 1Y
- 3Y
- All
Basic Details
Scheme Manager
Nikhil Mathur
Bench Mark
BSE Healthcare TRI
Type
OPEN
Lumpsum Returns
Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
---|---|---|---|---|---|---|
1 Week | 14 August 2025 | 10061.19 | 0.61% | - | 1.67% | 752/908 |
1 Month | 22 July 2025 | 9987.97 | -0.12% | - | -0.55% | 346/898 |
3 Month | 22 May 2025 | 10763.91 | 7.64% | - | 3.91% | 125/868 |
6 Month | 21 February 2025 | 11492.81 | 14.93% | - | 12.82% | 282/840 |
1 Year | 22 August 2024 | 11350.61 | 13.51% | 13.51% | -0.15% | 32/725 |
3 Year | - | - | 0% | - | 20.04% | -/- |
5 Year | - | - | 0% | - | 22.49% | -/- |
Since Inception | 4 October 2023 | 17430.00 | 74.30% | 34.28% | 13.54% | 7/910 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
---|---|---|---|---|---|
1 Year | 2 September 2024 | 1,20,000 | 129745.09 | 8.12% | 8.12% |
3 Year | - | - | - | - | - |
5 Year | - | - | - | - | - |
10 Year | - | - | - | - | - |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
- Investment type
- Scheme based
- SIP
- Lumpsum
Invested Amount
₹25,000
Estimated Returns
₹19,059
76%
Returns
Future value of your investment
₹44,059
Risk Ratios
4.86%
Standard Deviation
0.73%
Beta
1.78%
Sharpe Ratio
0.10%
Treynor's Ratio
23.20%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
---|---|---|---|---|---|
Sun Pharma.Inds. | 10.97% | 1244634 | 212.42 | Equity | Pharmaceuticals |
Divi's Lab. | 8.81% | 258490 | 170.49 | Equity | Pharmaceuticals |
Glenmark Pharma. | 7.42% | 672796 | 143.58 | Equity | Pharmaceuticals |
Cipla | 6.33% | 788343 | 122.56 | Equity | Pharmaceuticals |
Lupin | 5.98% | 599725 | 115.69 | Equity | Pharmaceuticals |
Ipca Labs. | 4.37% | 574492 | 84.67 | Equity | Pharmaceuticals |
Torrent Pharma. | 3.88% | 200598 | 75.06 | Equity | Pharmaceuticals |
Krishna Institu. | 3.82% | 984676 | 73.97 | Equity | Healthcare |
Laurus Labs | 3.64% | 806343 | 70.50 | Equity | Pharmaceuticals |
ERIS Lifescience | 3.55% | 381673 | 68.66 | Equity | Pharmaceuticals |
Peer Comparison
Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
---|---|---|---|---|---|---|---|
Nippon India Taiwan Equity Fund - Direct (G) | 351.43 | 9.17% | 23.59% | 20.10% | 29.89% | 25.43% | |
Nippon India Taiwan Equity Fund - Direct (IDCW) | 351.43 | 9.17% | 23.59% | 20.10% | 29.89% | 25.43% | |
Aditya Birla SL International Equity Fund - Direct (G) | 229.26 | 4.90% | 11.42% | 16.22% | 26.26% | 14.36% | |
Aditya Birla SL International Equity Fund - Direct (IDCW) | 229.26 | 4.90% | 11.42% | 16.22% | 26.26% | 14.36% | |
DSP Banking & Financial Services Fund - Dir (G) | 1346.44 | -2.42% | 1.62% | 14.69% | 18.79% | - |
List of Schemes under HDFC Mutual Fund
News
HDFC MF announces change in benchmark index under its scheme
HDFC Mutual Fund has announced change in the benchmark of HDFC Income Plus Arbitrage Active FOF with effect from, 30 August 2025Change in name of Benchmark of DSP Income Plus Arbitrage Fund of Fund
Scheme Name Existing Benchmark Revised Benchmark HDFC Income Plus Arbitrage Active FOF 35% NIFTY 50 Arbitrage Index + 60% NIFTY Composite Debt Index A-III + 5% NIFTY 1D Rate Index 40% NIFTY 50 Arbitrage Index + 60% NIFTY Composite Debt Index Powered by Capital Market - Live News
HDFC Mutual Fund announces change in scheme name
HDFC Mutual Fund has announced change in scheme name under the following scheme, With effect from 30 August 2025.Change in the name of the Scheme:
Existing Scheme Name Revised Scheme Name HDFC Developed World Equity Passive FOF HDFC Developed World Overseas Equity Passive FOF Powered by Capital Market - Live News
HDFC MF announces Income Distribution cum capital withdrawal (IDCW) under its scheme
HDFC Mutual Fund has announced 25 August 2025 as the record date for declaration of IDCW in the following scheme. The proposed IDCW on the face value of Rs 10 per unit will be:HDFC Balanced Advantage Fund:
Regular Plan ' IDCW: 0.250
Direct Plan ' IDCW: 0.250
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
14 September 2023
Total AUM (Cr)
₹1936.05
HDFC Pharma and Healthcare Fund - Regular (G) is an Sectoral / Thematic-oriented fund from the renowned AMC, HDFC Mutual Fund. Launched in 14 September 2023, this fund is managed by Nikhil Mathur. With assets under management (AUM) worth ₹1,936.05 (Cr), as of 25 August 2025, HDFC Pharma and Healthcare Fund - Regular (G) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 34.28% since its launch.
The current NAV of HDFC Pharma and Healthcare Fund - Regular (G) is ₹17.47, as on 25 August 2025. The fund's benchmark index is BSE Healthcare TRI. You can invest in HDFC Pharma and Healthcare Fund - Regular (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹100 while the minimum lumpsum investment is ₹100.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
In respect of each purchase/Switch-in of units, an Exit load of 1% is payable if units are redeemed/switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched-out after 30 days from the date of allotment. The fund has generated undefined% and undefined% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 98.20% in Equity, 2.09% in Debt and -0.29% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 77.77% in Pharmaceuticals & Biotech, 18.01% in Healthcare Services, 2.09% in Debt, 1.40% in Healthcare Equipment & Su, 1.02% in Insurance